InvestorsHub Logo
Followers 52
Posts 3332
Boards Moderated 0
Alias Born 10/26/2013

Re: klonk post# 2221

Wednesday, 06/13/2018 10:59:46 AM

Wednesday, June 13, 2018 10:59:46 AM

Post# of 3283
That's interesting. If there are any synergies of combining pozi and metformin, MD Anderson has a vested interested in finding them since they signed a licensing agreement with Spectrum last month.

http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-announces-exclusive-licensing-agreement

Edit - I should have added from your link MDAs involvement w metformin

This year’s ASCO featured 15 completed or planned studies of metformin in cancer care. And the Mexico City study, which included lung cancer patients with EGFR mutations, was just one of several trials suggesting the diabetes treatment may be useful in fighting some tumor types. For example, researchers from the University of Cincinnati Medical Center and the University of Texas MD Anderson Cancer Center found that combining metformin with chemo and radiation in patients with head and neck squamous cell carcinoma produced “an impressive impact on survival,”[4] according to the abstract.

Another MD Anderson group teamed up with researchers at the University of Florida to study the impact of metformin in patients over age 65 with diabetes and stage 4 colorectal cancer. They used a Medicare database to identify more than 1,800 seniors who were taking metformin while being treated for colon tumors between 2007 and 2013. Overall survival was better[5] among patients taking the diabetes treatment, they reported during ASCO.

https://unv.is/forbes.com/sites/arleneweintraub/2018/06/07/how-an-old-diabetes-drug-made-a-big-splash-at-cancers-biggest-confab